Idiot

DipShit

[Idiot @pukebot]

$ALLR
They sure seem to be putting a lot of resources into production and “deepening mechanism-of-action understanding for Stenoparib” if they are looking at the data in real time and it sucks

[Idiot @pukebot]

@DGretta_Author @usppdd Almost at your fib level!

[Idiot @pukebot]

@HeyRatty @NoaDalzell Dude “she’s” not going to fuck you. ( in the ass)

[Idiot @pukebot]

@Bambino_Bets Don’t you mean 18-4? Colorado last night?

[Idiot @pukebot]

@AlexJonesIA @BearingtonTrade Swish!

[Idiot @pukebot]

@OneBadDude_ This shit is as funny as pediatric cancer

[Idiot @pukebot]

$ALLR

Acquired 5 drug candidates?

from their website:

Our Approach to Value Creation

Step 1: Identifying clinical drug candidates with hidden potential

We start the journey of value creation by scouting for drug candidates with a documented acceptable safety profile and clinical efficacy data, but that failed to meet defined clinical trial endpoints as a result of study protocols failing to select the right patients. There are many options for drug candidates that meet these criteria, as the vast majority (95%) are placed on the shelf during development. Our search focuses on drugs or drug types for which we’ve already developed, or can easily develop, a DRP® companion diagnostic.

Step 2: In-licensing candidates with clear signals of efficacy and favorable safety profiles

So far, Allarity has been able to acquire five drug candidates for our portfolio with terms including low upfront fees, reasonable milestone and royalty payments, and access to existing clinical-grade drug supply. Many of our drug programs come from world-leading pharmaceutical companies, which we regard as an acknowledgment of the external trust in our ability to create significant
value based on drug candidates that have previously failed to be matched against an optimal patient group.

Step 3: Focused further development

After acquiring a new drug candidate, we employ a drug-specific DRP® companion diagnostic to focus the continued development for those patients who are expected to benefit most. We then
conduct a Phase 2 proof-of-concept (POC) study using the DRP® companion diagnostic to select and enroll patients most likely to respond to the drug. If the data supports advancing the program, we proceed to a DRP®-guided Phase 3/pivotal trial.

Step 4: Exiting programs with significant upside potential

In the final step of our business model, we exit drug programs through out-licensing, asset sale transfer, or M&A activity to global or regional pharmaceutical companies based on the results of DRP®–guided clinical trials. As a result of our proven ability to utilize a DRP® companion diagnostic to improve patient benefit for a drug program, we expect to receive substantial upside from program exit, which could include cash payments, royalties, etc.

[Idiot @pukebot]

@Stockspy1 Off by 12 hours lol

[Idiot @pukebot]

@Stockspy1 I’m mostly a lurker on this site so you wouldn’t see my engagement with your posts but you are absolutely one of the best accounts here and I can’t believe you don’t have 50k followers. Great work!

[Idiot @pukebot]

@JoeStonks You have been a total witch 🧙🏻 for months.

[Idiot @pukebot]

@daisyldixon Tattoos are retarded period. They look like shit on everyone

[Idiot @pukebot]

@sungleeiq IQ’s below 70 and above 270 are apparently clinically retarded.

[Idiot @pukebot]

$ALLR

Interesting article that paints a bleak picture lol. AI generated? Anyway I found it curious that it doesn’t mention the fully funded VA trial or the 3i deal in terms of cash runway

https://t.co/8Q7o3m57vo

[Idiot @pukebot]

$ALLR

Gotta say I’m very surprised and pleased 3i didn’t buy more shares. When I first read about the deal I wanted to puke. Dilution AND an incentive to mash down the price for 3 months. In retrospect not a bad deal for the company. $2.75 million @ around $1.55 a share but the arrangement doesn’t make any sense. Why have this potentially negative news floating around if they weren’t going to add significant shares? I’d love to hear what’s going on behind the scenes.

At any rate it’s interesting that this investment firm that got stiffed by Allarity back in 23/24 decided to give them another almost $3 million.
You would think they were told something positive by ALLR but who knows.

Hoping to thread the needle on this one. Get some good news from the FDA or otherwise before the company needs to raise more money.

[Idiot @pukebot]

@joancorn73 Unfortunately I don’t think until next quarterly which isn’t until March

[Idiot @pukebot]

$ALLR

When the window closes we’re gonna find out 3i bought how many dollars worth of shares?

[Idiot @pukebot]

@Heccles94 Staying out of women’s locker rooms is a choice

[Idiot @pukebot]

$ALLR

[Martin Shkreli @MartinShkreli]

Oh shit you were short? Why would you short a 20m market cap with FDA-approvable drug. Sorry man, you gotta learn somehow.

[Idiot @pukebot]

@WallStreetApes After your 3rd arrest, mandatory chip implant.

[Idiot @pukebot]

@webmasterdave @QualiaNerd @RichardDawkins How do we know they are even telling the truth? You want to carve out special rights for people who CLAIM to be something.